Development and Preclinical Evaluation of a Novel PET Probe for Phosphodiesterase 7B Imaging in Brain
- 20 August 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
Abstract
Phosphodiesterase 7B (PDE7B) is involved in the cAMP-PKA signaling pathway and has been implicated in neurodegenerative disorders. Accordingly, PDE7B represents a promising target for the development of therapeutics to treat such diseases. Recent efforts have led to the discovery of pyrimidinone-based compounds with high affinity and selectivity for PDE7B. In this study, we developed a novel pyrimidinone-based positron emission tomography (PET) probe, [11C]5. In vitro autoradiography using rat brain sections revealed specific binding of [11C]5 in the striatum and thalamus, consistent with the known distribution of PDE7B. Baseline PET scans showed relatively low brain uptake of [11C]5, except in the olfactory bulb. Pretreatment with elacridar, a potent dual inhibitor of drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), enhanced the brain uptake of [11C]5, resulting in further specific in vivo binding in the olfactory bulb and striatum. In conclusion, although the brain permeability of [11C]5 was limited by P-gp and BCRP, [11C]5 demonstrated specific binding to PDE7B, both in vitro and in vivo, supporting its potential utility for imaging PDE7B in the central nervous system.Keywords
Funding Information
- Japan Agency for Medical Research and Development (21zf0127003h)
- Japan Agency for Medical Research and Development (24zf0127012h)
- Japan Society for the Promotion of Science (23H02867)
- Japan Society for the Promotion of Science (23K07122)
- Japan Society for the Promotion of Science (23K27558)
- Japan Society for the Promotion of Science (24H00492)
- Japan Society for the Promotion of Science (24K21295)
This publication has 28 references indexed in Scilit:
- Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disordersInflammopharmacology, 2022
- Synthesis and preclinical evaluation of [11C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brainEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- A first-in-human study of 11C-MTP38, a novel PET ligand for phosphodiesterase 7European Journal of Nuclear Medicine and Molecular Imaging, 2021
- Sublamina‐specific organization of the blood brain barrier in the mouse olfactory nerve layerGlia, 2019
- ABC Family Transporters2019
- Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson’s DiseaseMolecular Neurobiology, 2019
- Chemistry for Positron Emission Tomography: Recent Advances in 11C‐, 18F‐, 13N‐, and 15O‐Labeling ReactionsAngewandte Chemie International Edition, 2019
- Differential distribution of cAMP‐specific phosphodiesterase 7A mRNA in rat brain and peripheral organsSynapse, 2001
- Cloning and Characterization of the Human and Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide PhosphodiesteraseBiochemical and Biophysical Research Communications, 2000
- Immunocytochemical evaluation of the blood-brain barrier to endogenous albumin in the olfactory bulb and pons of senescence-accelerated mice (SAM)Histochemistry and Cell Biology, 1996